Marker Therapeutics (NASDAQ:MRKR – Get Free Report) posted its quarterly earnings data on Friday. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.02, FiscalAI reports. The business had revenue of $0.75 million for the quarter, compared to the consensus estimate of $0.68 million. Marker Therapeutics had a negative net margin of 343.03% and a negative return on equity of 80.86%.
Marker Therapeutics Trading Down 2.7%
NASDAQ:MRKR opened at $1.42 on Friday. The company’s 50-day moving average price is $1.44 and its 200-day moving average price is $1.43. The company has a market cap of $23.67 million, a P/E ratio of -2.33 and a beta of 1.43. Marker Therapeutics has a twelve month low of $0.81 and a twelve month high of $4.07.
Hedge Funds Weigh In On Marker Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the business. Jane Street Group LLC purchased a new position in shares of Marker Therapeutics in the second quarter worth about $33,000. Virtu Financial LLC purchased a new position in shares of Marker Therapeutics in the third quarter worth about $25,000. Two Sigma Investments LP purchased a new position in shares of Marker Therapeutics in the third quarter worth about $33,000. XTX Topco Ltd lifted its stake in shares of Marker Therapeutics by 166.6% in the fourth quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock worth $86,000 after buying an additional 36,269 shares in the last quarter. Finally, LPL Financial LLC lifted its stake in shares of Marker Therapeutics by 41.7% in the fourth quarter. LPL Financial LLC now owns 83,247 shares of the company’s stock worth $124,000 after buying an additional 24,500 shares in the last quarter. 22.39% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Check Out Our Latest Research Report on MRKR
Marker Therapeutics Company Profile
Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.
Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.
Read More
- Five stocks we like better than Marker Therapeutics
- Japan’s Stealth Bull Market: How U.S. Investors Can Get Exposure
- 3 Stocks to Own If Gas Prices Keep Rising
- 3 Crucial Aerospace Component Makers That Analysts Love
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
Receive News & Ratings for Marker Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marker Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
